Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants

被引:43
作者
Gonzalo, RM
Rodríguez, D
García-Sastre, A
Rodríguez, JR
Palese, P
Esteban, M
机构
[1] CSIC, Ctr Nacl Biotecnol, Dept Cellular & Mol Biol, E-28049 Madrid, Spain
[2] CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
influenza and vaccinia virus recombinants; HIV-1; env; CD8(+) cells;
D O I
10.1016/S0264-410X(98)00274-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
With the aim to determine if immunization with two different live recombinant viral vectors could lead to an enhancement of the cellular immune response to HIV-1 antigens, we have characterized the CD8(+) T cell response elicited against the V3 loop epitope from HIV-1 env protein in Balb/c mice immunized with either: a recombinant influenza virus (Flu-Env) expressing the V3 loop epitope from HIV-1 strain IIIB, a vaccinia virus recombinant (VV-Env) expressing the complete HIV-1-IIIB enu protein, or a combination of both. The CD8(+) T cell response, measured by the ELISPOT assay, in animals primed with Flu-Env and boosted with VV-Env was 5 to 6 times higher than in animals inoculated with either Flu-Env or VV-Env alone. Similar results were obtained with recombinant viruses expressing the V3 loop epitope or the complete env protein, respectively, from the MN strain of HIV-1. Our results indicate that the use of two different live vectors for priming and boosting has a synergistic effect on the immune response against HIV-1, and could represent a novel vaccination strategy against AIDS. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:887 / 892
页数:6
相关论文
共 32 条
  • [1] Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1
    Berman, PW
    Murthy, KK
    Wrin, T
    Vennari, JC
    Cobb, EK
    Eastman, DJ
    Champe, M
    Nakamura, GR
    Davison, D
    Powell, MF
    Bussiere, J
    Francis, DP
    Matthews, T
    Gregory, TJ
    Obijeski, JF
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) : 52 - 59
  • [2] VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    CAO, YZ
    QIN, LM
    ZHANG, LQ
    SAFRIT, J
    HO, DD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) : 201 - 208
  • [3] QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE
    CARMICHAEL, A
    JIN, X
    SISSONS, P
    BORYSIEWICZ, L
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) : 249 - 256
  • [4] Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line
    Carroll, MW
    Moss, B
    [J]. VIROLOGY, 1997, 238 (02) : 198 - 211
  • [5] LYMPHOCYTE-T PRIMING AND PROTECTION AGAINST FRIEND-LEUKEMIA BY VACCINIA-RETROVIRUS ENV GENE RECOMBINANT
    EARL, PL
    MOSS, B
    MORRISON, RP
    WEHRLY, K
    NISHIO, J
    CHESEBRO, B
    [J]. SCIENCE, 1986, 234 (4777) : 728 - 731
  • [6] HIGH-EFFICIENCY FORMATION OF INFLUENZA-VIRUS TRANSFECTANTS
    ENAMI, M
    PALESE, P
    [J]. JOURNAL OF VIROLOGY, 1991, 65 (05) : 2711 - 2713
  • [7] ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.immunol.12.1.181
  • [8] VACCINE-INDUCED PROTECTION OF CHIMPANZEES AGAINST INFECTION BY A HETEROLOGOUS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    GIRARD, M
    MEIGNIER, B
    BARRESINOUSSI, F
    KIENY, MP
    MATTHEWS, T
    MUCHMORE, E
    NARA, PL
    WEI, Q
    RIMSKY, L
    WEINHOLD, K
    FULTZ, PN
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (10) : 6239 - 6248
  • [9] DRUG-THERAPY - CANDIDATE AIDS VACCINES
    GRAHAM, BS
    WRIGHT, PF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) : 1331 - 1339
  • [10] JAHAVERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768